Introduction
Thyroid hormone receptors (TRs) have key roles in normal physiology and development (Brent, 2000; Yen, 2001; Harvey and Williams, 2002; Buchholz et al., 2006; Flamant et al., 2006) . Two distinct genetic loci encode TRs, denoted a and b, each of which is alternatively spliced to generate additional receptor diversity. TRa1 and TRb1 are among the most abundant of these receptor isoforms, and exert distinct, if partially over-lapping, biological roles (Lazar, 1993; Murata, 1998; Yen, 2001; Harvey and Williams, 2002) . Both TRa1 and TRb1 bind to specific DNA sequences (response elements), and regulate the expression of adjacent target genes up or down (Katz and Koenig, 1993; Lazar, 1993 Lazar, , 2003 Yen, 2001 ). On 'positively regulated' target genes, TRs recruit corepressors and repress gene transcription in the absence of T3, but release corepressors, recruit coactivators and activate gene transcription in the presence of T3 (Cheng, 2000; Zhang and Lazar, 2000; Harvey and Williams, 2002; Tsai and Fondell, 2004) . There is less understanding of 'negatively regulated' target genes that are activated by TRs in the absence, but repressed in the presence, of hormone; this inverted T3 response presumably arises because of alterations in coregulator recruitment or function, perhaps reflecting combinatorial interactions with other transcription factors also arrayed on the same promoter (Meyer et al., 1997; Tagami et al., 1997; Berghagen et al., 2002; Nygard et al., 2003; Matsushita et al., 2007) .
Disruptions of TR function lead to disease (Yen and Cheng, 2003; Cheng, 2005) . Inherited mutations in the TRb locus result in human resistance to thyroid hormone syndrome, an endocrine disorder (Refetoff, 1993; Refetoff et al., 1993; DeGroot, 1996; Kopp et al., 1996; Yen, 2003) . A virally transduced mutant form of TRa contributes to leukemogenesis by the avian erythroblastosis retrovirus (Graf and Beug, 1983; Sap et al., 1986; Weinberger et al., 1986; Damm et al., 1989; Privalsky, 1992) . Spontaneous mutations in TRa and TRb are found at high frequency in human hepatocellular carcinomas (HCCs), renal clear cell carcinomas, and certain thyroid malignancies and are believed to participate in the initiation or progression of these malignancies (Lin et al., 1996 (Lin et al., , 1999 Kamiya et al., 2002; Puzianowska-Kuznicka et al., 2002; Cheng, 2003; Gonzalez-Sancho et al., 2003; Chan and Privalsky, 2006) . Virtually, all of these TR mutants are impaired in the ability to exchange coactivator for corepressor in response to physiological concentrations of T3. As a result, the mutant receptors retain corepressor inappropriately and can function as dominant-negative inhibitors of wild-type receptor function (Lin et al., 1996 (Lin et al., , 1997 Chan and Privalsky, 2006; Privalsky, 2008) .
Given this commonality, why do certain dominantnegative TRs produce primarily endocrine disease, whereas others are closely associated with neoplasia? Notably, the mutant TRs found in resistance to thyroid hormone syndrome represent single mutational events, whereas the mutant TRs found in neoplasia are typically aggregates of multiple genetic lesions, often including mutations in the DNA recognition domain of these receptors (Refetoff, 1993; Lin et al., 1999; Kamiya et al., 2002; Puzianowska-Kuznicka et al., 2002; Yen and Cheng, 2003) . We have proposed that single TR mutations give rise to simple dominant-negative receptors that produce endocrine disorders, whereas additional mutations further modify the dominant-negative phenotype, at least in part by altering target gene recognition, to generate the neoplastic phenotype (Chan and Privalsky, 2006; Privalsky, 2008) . To test this hypothesis, we used a microarray analysis to compare the target gene profiles of wild-type and HCC mutant TRs. We report that the HCC-TR mutants tested showed widespread alterations in their target gene repertoire compared with the corresponding wild-type controls, and we discuss how these changes may contribute to oncogenesis.
Results
The HCC-TR mutants are impaired in transcriptional activation and act as dominant-negative inhibitors of wild-type TRs in reporter assays HepG2 are a well-characterized human HCC cell line that lacks known TR mutations and expresses modest levels of wild-type TRa1 and TRb1 (Chamba et al., 1996; Lin et al., 1996) . We generated stable HepG2 transformants expressing a representative HCC-TRa1 mutant (denoted TRa1-I), a representative HCC-TRb1 mutant (denoted TR-b1-N), wild-type TRa1 (TRa1-WT), wild-type TRb1 (TRb1-WT), or an empty expression vector control ( Figure 1a ). We first examined the overall T3 response in these cells using a luciferase reporter containing an archetypal DR4 positiveresponse element (Figure 1b ). The HepG2 transformants containing the empty expression plasmid showed a low level T3-mediated regulation of this reporter mediated by the endogenous TRs present in these cells (Darby et al., 1991; Theriault et al., 1992) . Transformants bearing the TRa1-WT constructs showed a significantly enhanced T3 response ( Figure 1b ); a similar, although more modest T3 response was also observed for TRb1-WT ( Figure 1b ). In contrast, HepG2 transformants expressing the TRa1-I or TRb1-N mutants showed reduced levels of reporter expression in the absence of T3 compared with the empty-vector controls, and a severely attenuated reporter gene activation in response to T3. These results support previous findings that these HCC-TR mutants are impaired for T3-induced transcriptional activation (Chan and Privalsky, 2006) .
The HCC-TR mutants repress only a subset of the genes repressed by wild-type TRs in the absence of T3, and have gained a novel ability to repress additional targets not recognized by wild-type TRs We next compared the patterns of cellular gene expression in our HepG2 transformants by use of a microarray analysis. The TRa1-I and TRb1-N mutants have been suggested to operate in cancer by constitutively mimicking the repressive functions mediated by the wild-type receptors in the absence of T3 (Chan and Privalsky, 2006) . Therefore, we first identified the cellular genes repressed by the mutant TRs relative to the empty-vector transformants, and compared these genes to those repressed by the wild-type TRs relative to the empty-vector transformants, all in the absence of T3 (symbolized as kTR -T3 ) (Figures 2a and b ). Representative target genes were confirmed by reverse transcriptase-PCR (RT-PCR) ( Figure 2c and data not shown). Notably, several genes, such as BICC1, were strongly repressed by all TRs tested (Figures 2b and c) . However, other genes were repressed by the wild-type TR, but not by the corresponding mutant under these conditions. For example, DOCK9 was repressed by TRa1-WT but not TRa1-I, and PROM1 was repressed by both TRa1-WT and TRb1-WT, but not by either mutant (Figures 2b and c) . Reciprocally, certain genes were selectively repressed by the mutant version of a given receptor: for example, CDCA7L was repressed only by the TRa1-I mutant, and not by TRa1-WT, whereas SLC2A2 was preferentially repressed by the TRb1-N mutant compared with TRb1-WT (Figures 2b and c) . A more comprehensive list of all genes described in this study is provided in Supplementary Table S2 . Figure 1 The human hepatocellular carcinoma-thyroid hormone receptor (HCC-TR) mutants are impaired in transcriptional activation. (a) Schematic of wild-type and mutant TRs. The different TRs are depicted with the locations of the DNA binding (DBD), hormone-binding domain (HBD) and HCC mutations indicated. (b) Impaired reporter activation in HCC mutant TR transformants. HepG2 cells stably integrated with TRa1-WT, TRb1-WT, TRa1-I, TRb1-N or an empty-plasmid control (noreceptor (NR)) were transiently transfected with a DR4-TKluciferase reporter and pCH110 as an internal control. The cells were treated 24 h later with T3 or vehicle alone, harvested 48 h after transfection, and the luciferase activity was determined relative to b-galactosidase activity (mean þ s.e.m., n ¼ 3).
These results support our hypothesis that the mutant receptors are selective dominant-negatives able to repress some, but not all the genes repressed by their wild-type progenitors. Significantly, our data also showed an additional, if limited, capability of the mutant receptors to repress target genes that were not repressed by the corresponding wild-type receptors, indicating that the mutations in these receptors did not simply narrow, but actually redirected their target gene repertoire.
We next examined the effect of T3 on the same panel of genes that were repressed by TRs in the absence of this hormone. As anticipated from our reporter gene assays, the TRa1-I and TRb1-N mutants behaved as hormone-independent, constitutive repressors (kTR -T3 remained kTR þ T3 ) on most of their cellular target genes (for example, CDC7AL for TRa1-I and TRb1-N, or BHMT2 for TRa1-I) (Figures 3c-e, Supplementary  Table S2 ). In contrast, repression by the wild-type receptors was at least partially reversed by T3 for certain target genes (for example, ERRFI1 for both TRa1-WT and TRb1-WT, and, to a lesser extent, DOCK9 for TRa1-WT; Figures 3a and b , Supplementary Table S2 ). However, other wild-type TR target genes behaved constitutively and were equally repressed by the wildtype receptor in both the absence and presence of T3 (for example, CAP2 for TRa1-WT or BHMT2 for TRb1-WT; Figures 3d and e ). These results were confirmed for representative genes by RT-PCR (data not shown). Target genes that are repressed more strongly in response to T3 than in its absence (that is, negatively regulated genes; kTR -T3 changes to kkTR þ T3 ) are discussed separately, below. We conclude that wild-type TRs possess a mix of hormone-independent and hormone-reversible repressive properties, with the latter largely absent for the HCC mutants.
The HCC mutant TRs are not exclusively transcriptional repressors, but are also able to activate a limited set of target genes in the presence of T3 Although several of the genes characterized above were derepressed by T3, most were not activated by T3 above the empty-vector controls. We therefore next searched for TR gene targets that were upregulated above basal levels by T3 (that is, mTR þ T3 ) (Figures 4a and b, and validated by RT-PCR, Figure 4c ). As expected, TRa1-I and TRb1-N failed to induce many of the cellular genes induced by the corresponding wild-type receptors under these conditions (for example, PTAFR, Figures 4b and c). Figure 2 In the absence of T3, the human hepatocellular carcinoma-thyroid hormone receptor (HCC-TR) mutants repress a distinct set of genes compared with wild-type TRs. (a) Venn diagram of gene transcripts downregulated in each TR transformant compared with the empty-vector (no-receptor (NR)) control, all in the absence of T3. HepG2 cells transformed with the TR alleles indicated, or with the empty-plasmid control, were incubated in the absence of T3 (vehicle only) for 6 h; RNA was isolated, and used to probe the arrays. Transcripts downregulated in each TR transformant compared with the empty-vector control (NR) were identified using a Benjamini-Hochberg adjusted P-value of o0.05. (b) Heat map clustering of the genes from panel (a). For each gene, dark blue indicates lowest expression, dark red indicates highest expression, with intermediate values represented by lighter shades. These comparisons were -T3; asterisks indicate genes that were also downregulated in the presence of T3 (see Figure 6 ). (c) Reverse transcriptase-PCR (RT-PCR) on representative genes identified in panel (b), using gene-specific primers. The level of expression of each gene product was defined as '1' for the empty-vector control in the absence of T3 (mean þ s.e.m., n ¼ 3). An '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05.
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However, these mutants retained an unanticipated ability to activate several of the same genes activated by the wild-type TRs (for example, HEPACAM, Figure 4b , and by RT-PCR, Figure 4c ), and actually gained an ability to activate a novel set of target genes not regulated by the wild-type TRs (for example, GNG12; Figure 4b , and by RT-PCR, Figure 4c ). Further comparison of this same panel of genes in the absence as well as in the presence of T3 revealed more information ( Figure 5 ). As expected, many of the genes regulated by the wild-type receptors were expressed at higher levels in the presence of T3 than in its absence. This grouping included genes activated by receptor in the absence of T3, but expressed at still higher levels in the presence of T3 (that is, mTR ÀT3 changes to mmTR þ T3 ), such as ENPP2 ( Figure 5a ). It also included genes expressed at basal levels (that is, equal to empty-vector controls) in the absence of T3, and induced above basal only in the presence of T3 (that is, basalTR ÀT3 changes to mTR þ T3 ), such as ANGPTL2 and PPL (Figures 5b and c). Yet other target genes were activated by the wild-type TRs essentially independent of T3 status (that is, mTR ÀT3 remains mTR þ T3 ), such as CYBD1 ( Figure 5d ). Although most of the targets activated by the HCC-TR mutants fell into this constitutively activated category, a subset of HCC-TR target genes retained a residual hormone response and were more strongly activated plus T3 versus minus T3 (mTR ÀT3 became mmTR þ T3 ; for example, FYN and SGK, Figures 5e and f). Representative genes were confirmed by RT-PCR (data not shown). Genes that were more strongly repressed in the presence of T3 (that is, negatively regulated genes) are described below. We conclude that the HCC mutant TRs unexpectedly retain an ability to activate a subset of the genes induced by the corresponding wild-type receptor, and have also gained an ability to activate a novel, although limited, repertoire of additional genes not activated by the wild-type TRs. Microarray intensity signal values (mean þ s.d., n ¼ 3) are presented for HepG2 transformants bearing each of the thyroid hormone receptor (TR) expression vectors indicated. The '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05.
The HCC-TR mutants regulate a narrow subset of the T3-repressed, negative-response genes that are targeted by the wild-type TRs Genes possessing 'negative-response elements' operate reciprocally to the positive-response genes described above: they are preferentially repressed in the presence of T3, or preferentially activated in the absence of T3. To capture these additional TR targets, our next step was to identify the genes repressed by mutant or wildtype receptors in the presence of T3 (kTR þ T3 ). This parsing found both overlap and divergence between the genes targeted by the wild-type versus the mutant TRs Figure 4 The human hepatocellular carcinoma (HCC) mutant thyroid hormone receptors (TRs) are able to upregulate a distinct subset of target genes in the presence of T3. (a) Venn diagram of gene transcripts upregulated in each TR transformant compared with the empty-vector (no-receptor (NR)) control, all in the presence of T3. HepG2 cells transformed with the TR alleles indicated, or with the empty-plasmid control, were incubated with T3 for 6 h; RNA was isolated, and used to probe the arrays. Transcripts upregulated in each TR transformant compared with the empty-vector control (NR) were identified using a Benjamini-Hochberg adjusted P-value of o0.05. (b) Heat map clustering of the genes from panel (a). For each gene, dark blue indicates lowest expression, dark red indicates highest expression, with intermediate values represented by lighter shades. These comparisons were þ T3; asterisks indicate genes that were also upregulated in the absence of T3 (see Figure 7 ). (c) Reverse transcriptase-PCR (RT-PCR) on representative genes identified in panel (b), using gene-specific primers. The level of expression of each gene product was defined as '1' for the empty-vector control in the absence of T3 (mean þ s.e.m., n ¼ 3). An '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05; ' # ' indicates a P-value p0.1.
( Figure 6 ). Notably, most of the target genes repressed by TRs in the presence of T3 were identified earlier in Figure 2 as repressed by TRs in the absence of T3 (identified by asterisks in Figures 2b and 6b) ; the majority of these are hormone non-responsive genes (kTR ÀT3 remains kTR þ T3 ), rather than negative-response genes per se ( Figure 6 and Supplementary Table  S2 ) and have already been discussed. However, several genes (such as ANKRD1 and PROM1, Figure 6c ) were reproducibly more strongly repressed in the presence than in the absence of T3 (kTR ÀT3 changed to kkTR þ T3 ). The mutant TRs showed an attenuated, although often still detectable, negative response to T3 on several of these same genes (Figure 6c , Supplementary Table S2 ).
Our final comparison was to identify the genes that are selectively activated by receptors in the absence of T3 (mTR ÀT3 ) (Figure 7) . A significant number of the targets identified earlier in Figure 4 as induced by the mutant or wild-type receptors in the presence of T3 were also induced in its absence (Figure 7 and Supplementary  Table S2 ). Many of these targets are not negativeresponse genes per se, but rather fall into the two subclasses of positive-response genes already discussed: those that are constitutively upregulated in a hormoneindependent manner (mTR ÀT3 remain mTR þ T3 ), and those that are upregulated in the absence of hormone, and further upregulated in the presence of T3 (mTR ÀT3 change to mmTR þ T3 ); these are indicated by asterisks in Figures 4b and 7b . Although much more rare, genes that do fit our definition of negative regulation, preferentially upregulated in the absence, relative to the presence, of T3 (mmTR ÀT3 changes to mTR þ T3 or mTR ÀT3 changes to basalTR þ T3 ), were also identified. These included genes Figure 4 . Microarray intensity signal values are presented (mean þ s.d., n ¼ 3) are presented for HepG2 transformants bearing each of the TR expression vectors indicated. An '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05.
Altered gene recognition by TR mutants in HCC IH Chan and ML Privalsky regulated preferentially by the wild-type receptors (for example, APCDD1, Figure 7c ) or preferentially by the mutant receptors (for example, GLT25D2 and CX3CR1, Figure 7c ; TRa1-WT showed little or no regulation of these genes, whereas TRb1-WT showed an attenuated response compared with the two TR mutants).
We conclude that the HCC TRa1-I and TRb1-N mutants are generally restricted to a narrower panel of target genes and a narrower dynamic range of transcriptional output than are the wild-type TRs. Nonetheless, both TRa1-I and TRb1-N have also acquired an ability to target novel genes not regulated by the wildtype receptors, and can regulate a subset of their target genes up or down at least as strongly as can their wildtype TR progenitors.
The perturbed gene expression mediated by the HCC-TR mutants parallel known alterations of the transcriptosome found in primary HCC tumors At least seven of the genes we identify as expressed at higher levels in the HCC-TR mutant transformants compared with wild-type (that is, either activated by the mutant TRs but not by the wild-type TRs, or repressed by the wild-type TRs but not by the mutant TRs) have been identified earlier as upregulated in primary HCC tumors (Table 1) . At least eight of the genes we identify as expressed at lower levels in the TR-HCC mutants compared with wild-type TRs (that is, genes activated by wild-type TRs but not by the mutants) have been identified earlier as downregulated in primary HCC tumors (Table 1) . A yet-additional panel of the target genes aberrantly regulated by the TR mutants studied here, although not previously reported to be associated with HCC, have been implicated in other forms of neoplasia (Table 2 and Supplementary Table S3 ). These comparisons support the relevance of our cell culture analysis to the tumor transcriptosome in vivo, and suggest that the altered gene repertoire of the TR mutants likely contributes to the overall changes in gene expression characteristic of HCC.
Discussion
Thyroid hormone receptor mutants implicated in human HCC are selective antimorphs, repressing only a subset of the genes targeted by wild-type TRs Dominant-negative mutant TRs have roles in resistance to thyroid hormone syndrome, avian erythroleukemia, HCC, RCCC and thyroid cancers (Graf and Beug, 1983; Zenke et al., 1990; Lin et al., 1999; Rietveld et al., 2001; Kamiya et al., 2002; Puzianowska-Kuznicka et al., 2002; Yen and Cheng, 2003; Chan and Privalsky, 2006) . What accounts for the ability of certain of these TR mutants to induce neoplasia, whereas others are exclusively associated with endocrine disorders? Notably, the mutant TRs isolated from human HCCs function not only as dominant-negative inhibitors on certain reporter genes but often have sustained additional mutations that alter their DNA recognition properties (Chan and Privalsky, 2006) . A similar phenomenon was observed for the oncogenic v-Erb A allele and for certain RCCC-TR mutants (Bonde and Privalsky, 1990; Sharif and Privalsky, 1991; Chen et al., 1993; Ventura-Holman et al., 2008; Rosen and Privalsky, 2009 ). In fact, v-Erb A, when expressed in transgenic mice, induces HCC Figure 6 The mutant and wild-type thyroid hormone receptors (TRs) negatively regulate distinct sets of target genes in response to T3. (a) Venn diagram of gene transcripts downregulated in each TR transformant compared with the empty-vector (no-receptor (NR)) control, all in the presence of T3. HepG2 cells transformed with the TR alleles indicated, or with the empty-plasmid control, were incubated with T3 for 6 h; RNA was isolated, and used to probe the arrays. Transcripts downregulated in each TR transformant compared with the empty-vector control (NR) were identified using a Benjamini-Hochberg adjusted P-value of o0.05. (b) Heat map clustering of the genes from panel (a). For each gene, dark blue indicates lowest expression, dark red indicates highest expression, with intermediate values represented by lighter shades. These comparisons were þ T3; asterisks indicate genes that were also downregulated in the absence of T3 (see Figure 2 ). (c) Expression levels, minus or plus T3 treatment, of representative gene transcripts from the genes identified in panel (b). Microarray intensity signal values are presented (mean þ s.d., n ¼ 3). An '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05.
Altered gene recognition by TR mutants in HCC IH Chan and ML Privalsky (Barlow et al., 1994) . We hypothesized that these changes might confer an altered target gene repertoire that contributes to the ability of these receptors to induce neoplasia. We report here an analysis of target gene expression in HepG2 cells expressing wild-type or mutant TRs. This approach confirmed a key aspect of our working hypothesis: the TRa1-I and TRb1-N mutants each repressed only a subset of the cell genes repressed by the corresponding wild-type receptors, and repression by the mutants was typically independent of hormone. This result is consistent with our reporter experiments and with in vitro data that the TRa1-I mutant binds to a more narrow set of natural and artificial DNA-binding elements than does WT-TRa1 (Supplementary Figure  S1 and Chan and Privalsky, 2006) . Notably, our approach also identified an additional set of target genes repressed by the TRa1-I or TRb1-N mutants but not by the wild-type receptors. TRa1-I binds better to at least one artificial DNA sequence than does TRa1-WT (Supplementary Figure S1 and Chan and Privalsky, 2006) , and it is likely these HCC-TR cellular Figure 7 The mutant and wild-type thyroid hormone receptors (TRs) positively regulate distinct sets of target genes in the absence of T3. (a) Venn diagram of gene transcripts upregulated in each TR transformant compared with the empty-vector (no-receptor (NR)) control, all in the absence of T3. HepG2 cells transformed with the TR alleles indicated, or with the empty-plasmid control, were incubated in the absence of T3 (vehicle only) for 6 h; RNA was isolated, and used to probe the arrays. Transcripts upregulated in each TR transformant compared with the empty-vector control (NR) were identified using a Benjamini-Hochberg adjusted P-value of o0.05. (b) Heat map clustering of the genes from panel (a). For each gene, dark blue indicates lowest expression, dark red indicates highest expression, with intermediate values represented by lighter shades. These comparisons were -T3; asterisks indicate genes that were also upregulated in the presence of T3 (see Figure 4 ). (c) Expression levels, -T3 or þ T3 treatment, of representative gene transcripts from the genes identified in panel (b) . Microarray intensity signal values are presented (mean þ s.d., n ¼ 3). An '*' indicates that the difference between the TR transformant and the empty-vector control was significant at a P-value p0.05.
target genes possess related, mutant-specific response elements.
Therefore, the mutations in the HCC-TR mutants have not simply narrowed their gene recognition properties, but have also shifted them to encompass novel targets. We favor the model that this altered target gene repertoire arises primarily from the altered DNA sequence recognition properties of these HCC-TR mutants; however, we cannot exclude the possibility that alterations in transcriptional regulation after DNA binding may also contribute. For example, a coactivator required for activation of a specific subset of target genes may be recruited by the wild-type but not by the mutant TRs.
Unexpectedly, the HCC-TR mutants were able to activate transcription of a subset of the target genes induced by the wild-type receptors, plus an additional set of mutant-specific target genes Our study also identified genes whose expression was increased by the introduction of a given TR. A subset of these genes were induced by the wild-type TRs more strongly in the presence than in the absence of T3, presumably reflecting the actions of the T3-dependent 'AF-2' activation domain within the receptor hormonebinding domain (Yen, 2001) . Interestingly, a second panel of target genes were constitutively upregulated by the wild-type TRs independent of T3 status; this category may represent the actions of the TR Altered gene recognition by TR mutants in HCC IH Chan and ML Privalsky N-terminal 'AF-1' domain, which is known to mediate hormone-independent transcriptional activation (Yen, 2001) . Our results support previous studies indicating that wild-type TRs exert a spectrum of possible responses to hormone ranging from derepression to activation (Yen, 2001) . Unexpectedly, a panel of genes was also induced above basal levels by introduction of the HCC mutant receptors. These mutant-activated genes were generally a subset of those activated by the wild-type TRs, although a few were unique to a given mutant receptor. Most were activated by the mutant receptors in a T3-independent manner, perhaps through the actions of the AF-1 domain, which is untouched by the mutations in TRa1-I and TRb1-N. However, a narrow subset of these target genes was activated more strongly by the HCC mutant receptors in the presence versus the absence of hormone. This is a particularly unexpected result for the TRa1-I mutant, which is largely incapable of activation in artificial reporter gene assays (Chan and Privalsky, 2006) . However, the TRa1-I mutant retains the ability to bind hormone in vitro, and it is possible that the remnants of the AF-2 domain in this mutant are sufficient to mediate a T3 response on certain promoters. Alternatively, endogenous TRs are present at low levels in the HepG2 cells (Chamba et al., 1996) ; it is possible that dimers may form between mutant and endogenous TRs, with the endogenous TR partner conferring a T3-response on target genes determined by the mutant TR partner.
We conclude that the HCC-TR mutants can behave both as constitutive repressors on certain target genes, and as constitutive activators on others. In much more restricted circumstances, these same mutants also show a residual T3 response on a specific subset of their target gene repertoire. This opens the possibility that certain aspects of the HCC neoplastic phenotype may be responsive to treatment with TR agonists or antagonists, an issue that should be examined further in future studies.
The altered gene repertoire of the HCC-TR mutants extends to negative-response genes and reveals divergent modes of target gene recognition An additional category of TR targets, denoted negativeresponse genes, are expressed at lower levels in the presence versus the absence of T3, and have been implicated in the ability of wild-type TRs to suppress cell proliferation in response to T3. Although relatively few of these negative-response genes were detected by our array approach, we did observe examples in all three possible categories: targets negatively regulated by T3 only in the wild-type TR transformants, only in the mutant TR transformants or in both types of transformants. These results extend our previous observations using a prototypic negative-response reporter derived from the collagenase promoter (Chan and Privalsky, 2006) .
Thyroid hormone receptors are believed to be recruited to many negative-response genes through protein-protein interactions with other transcription factors, rather than by direct DNA binding (Desbois et al., 1991; Sharif and Privalsky, 1992) . Notably, TRa1-I has a substitution in a highly conserved lysine (codon 74). K74 is located in the receptor DNA recognition helix and makes base-specific contacts in the major groove of the DNA-binding site (Rastinejad et al., 1995) . As a result, it is not surprising that the TRa1-I mutant shows an altered recognition of genes regulated through direct receptor/DNA contacts (presumably the bulk of the positive-response genes identified here). However, K74 has been shown to also exert unusual functions on negative-response genes. An artificial lysine to alanine substitution in TRa1 (K74A) converts the mutant TR from a negative-response regulator of the collagenase promoter into a positive-response regulator (Uht et al., 2004) . It has been suggested that the wildtype lysine at codon 74 may contribute to the direction of the hormone response by sensing whether nuclear receptors are bound to DNA (a positive-response gene) or not (a negative-response gene) (Starr et al., 1996; Meyer et al., 1997) . At least some of the alterations in cellular gene regulation observed in our current study may reflect the dual roles of this lysine both as a sensor and as a mediator of DNA binding.
The TRa1-I and TRb1-N mutants have both convergent and divergent target repertories Mutations in TRa1 and in TRb1 occur separately in certain HCC tumors, indicating that aberrant regulation by either isoform may contribute to neoplasia (Lin et al., 1999) . In fact, certain genes identified here, such as PROM1, were regulated by both wild-type receptor isoforms, but not by either mutant; conversely other genes were targeted by both mutants, but by neither wild-type isoform, such as GNG12. These shared gene targets define a common mechanism through which either mutant might independently contribute to establishment of the oncogenic phenotype. Nonetheless, approximately 47% of HCCs bear mutations in both TR isoforms, suggesting that mutations in TRa1 and TRb1 can also work together to exert complementary roles in a single tumor (Lin et al., 1999) . In fact, other sets of the target genes characterized here were regulated by one or the other mutant but not by both, perhaps helping to explain how two mutant TRs operating together might be better than either one operating separately in tumorigenesis.
What roles do these genes have in cancer initiation or progression? Wild-type TRs can act as inhibitors of tumor invasiveness, metastasis and proliferation (Garcia-Silva and Aranda, 2004; Martinez-Iglesias et al., 2009) ; one role of these TR mutants, therefore, may be to interfere in a dominant-negative manner with the antiproliferative properties of the wild-type TRs. Consistent with this proposal, our TRa1-WT transformants were inhibited for anchorage-independent growth, whereas the TRa1-I transformants were not (Chan and Privalsky, 2006) . Perhaps also reflecting the same phenomenon, we noted a slight bias against the wild-type TRs when generating our stable HepG2 transformants: 31% of the G418 clones were TRa1-WT positive and 34% were TRb1-WT positive, whereas 45% were TRa1-I positive and 42% were TRb1-N positive.
Prior studies on thyroid and pituitary neoplasia associated with mutant TR expression have implicated several specific pathways that contribute to tumor suppression by wild-type TRs and to tumor promotion by TR mutants, such as alterations in Wnt signaling, cyclin D1 regulation and phosphatidylinositol 3-kinase (PI3 K) activity (Miller et al., 2001; Furumoto et al., 2005; Furuya et al., 2006) . Our current study is consistent with this concept that the HCC-TR mutants function, in part, by counteracting the growth suppressive properties of the wild-type TRs. However, we also show that the HCC-TR mutants can regulate novel genes not recognized by the wild-type receptors, and may also operate through novel, pro-oncogenic pathways. A partial list of the genes we identify here as aberrantly regulated by the HCC-TR mutants, and which have been implicated earlier in various aspects of oncogenic signaling, is provided in Tables 1 and 2. Among these are tumor suppressors in the Wnt signaling pathway (DKK1 and WT1), known oncogenes (PAK1 and SGK) and genes involved in other features of cancer such as metastasis (VCAN) and survival (AGR2) (Vadlamudi and Kumar, 2003; Lee et al., 2004; Vogelstein and Kinzler, 2004; Zhang et al., 2005; Mikheev et al., 2008; Ramachandran et al., 2008; Ricciardelli et al., 2009) . More analysis will be required to determine the precise role of these targets in HCC, their relationship to other cancers associated with mutant TRs, and their significance relative to the growth regulatory properties of the wild-type TRs.
Materials and methods
Isolation of stable transformants, microarray analysis, and reporter assay The HepG2 transformants bearing pCIneo constructs of human wild-type TRa1, wild-type TRb1, TRa1-I, TRb1-N or an empty-plasmid control were generated using a G418 coselection methodology (Chan and Privalsky, 2006) . Individual cell clones were propagated and screened for integration and expression of the TRs by PCR/RT-PCR. In all, 6 to 12 independent cell clones positive for the expression of each receptor were pooled and were treated with 100 nM T3 or with ethanol carrier alone for 6 h in DMEM containing 10% hormone-stripped fetal bovine serum (this time period was chosen to focus primarily on direct-response genes). The cells were harvested and RNA was isolated using an RNeasy kit (Qiagen Inc., Valencia, CA, USA). The purified RNA was submitted to the Cancer Center Gene Expression Resource, University of California, Davis, for subsequent complementary DNA probe generation, hybridization to and scanning of Affymetrix GeneChip Human Gene 1.0 ST microarrays (Affymetrix Inc., Santa Clara, CA, USA). Raw microarray data were normalized by the Robust Multichip Array method and P-value adjustments were performed by the Benjamini-Hochberg method using R software and the affylmGUI package (available at http://www.bioconductor.org/ and http://www.r-project.org/; Irizarry et al., 2003; Smyth, 2004) . Heat maps were generated with GenePattern (Reich et al., 2006) . Three independent biological repeats were analysed for each of the five transformant pools. Luciferase reporter assays were performed by transient transfection of these stable transformants (Chan and Privalsky, 2006) .
Reverse transcriptase-PCR
The RNA was isolated from cells using Qiagen's RNeasy kit using the manufacturer's protocols (Qiagen Inc.). Complementary DNA was synthesized using Qiagen's QuantiTect kit and 1 mg RNA. Semi-quantitative RT-PCR was performed using GoTaq DNA Polymerase (Promega, Madison, WI, USA) and the primer sequences listed in Supplementary Table S1 . PCR products were analysed on 8% Tris-acetate-EDTA polyacrylamide gels, stained with SYBR green, and quantified with a Flurochem8900 Imager (Alpha Innotech, San Leandro, CA, USA).
